89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma

Sponsor
University Medical Center Groningen
Study ID
NCT01859234
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 89Zr-bevacizumab — DRUG
    89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.

Study Details

The purpose of this study is to see whether 89Zr-bevacizumab PET scanning is feasible in relapsing multiple myeloma patients.

Key Dates

First listed
May 21, 2013
Start date
May 31, 2013
Status verified
May 2013
Primary completion
May 31, 2014

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: 89Zr-bevacizumab PET scan
    all patients included in the study will have a 89Zr-bevacizumab PET scan

Primary Outcome Measure

Focal lesion of 89Zr-bevacizumab PET scanning in patients with relapsing multiple myeloma [ Time Frame: during scanning ]

Central Contacts

Related Studies